scholarly journals Non-Small Cell Lung Cancer Classification from Histopathological Images using Feature Fusion and Deep CNN

Lung cancer is the overgrowth of cells in digestive organs. Identifying different types of lung cancer (squamous cell cancer, large cell carcinoma and adenocarcinoma) from lung histopathological images is outrageous works that shorten the chance of infected with lung cancer in the future. This research propounds an accurate diagnosis scheme using various neural network features and fusion of contourlet transform from lung histopathological image. This lesson has used several pre-train models (Alexnet, ResNet50, and VGG-16) in addition to divers scratch models while the pre-train Resnet50 model works better. The two reduction techniques (Principle Component Analysis (PCA) and Minimum Redundancy Maximum Relevance (MRMR)) have used to classify the type of lung cancer with the extraction of the most significant properties. In Convolution Neural Network (CNN) based lung cancer detection, the reduction approach PCA performs better. This proposed methodology is performed on ordinary datasets and establishes comparative better performance. The accuracy of this paper is 98.5%, sensitivity 96.50, specificity 97.00%, which is more effective than other approaches.

2020 ◽  
Vol 12 (02) ◽  
pp. 4549-4554
Author(s):  
Amin Saif ◽  
Yakoop Razzaz Hamoud Qasim ◽  
Habeb Abdulkhaleq Mohammed Hassan Al-Sameai ◽  
Osamah Abdo Farhan Ali ◽  
Abdulelah Abdulkhaleq Mohammed Hassan

1985 ◽  
Vol 3 (11) ◽  
pp. 1478-1485 ◽  
Author(s):  
D Osoba ◽  
J J Rusthoven ◽  
K A Turnbull ◽  
W K Evans ◽  
F A Shepherd

Fifty-three patients with recurrent and advanced stage (III and IV) non-small-cell lung cancer (NSCLC) were treated with a combination of bleomycin, etoposide (VP-16-213), and cis-diamminedichloroplatinum (BEP). Forty-eight patients were appraisable for response. The response rates were 44% for the entire group, 57% in 30 patients with combined squamous-cell and large-cell carcinoma, and 22% in 18 patients with adenocarcinoma (40%, 50%, and 19%, respectively, if patients not appraisable for response are included as nonresponders). The median survival time of patients with squamous-cell and large-cell carcinoma was slightly longer than that of patients with adenocarcinoma (23 weeks v 19 weeks). Patients with responsive disease survived significantly longer (median, 34 weeks) than did patients with unresponsive disease (median, 16 weeks) (P = .001). In the entire group, the median survival time of patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 was better (23 weeks) than of those with a status of 2 or 3 (15 weeks), but this difference was not seen in the subgroup with squamous-cell and large-cell carcinoma (24 weeks v 23 weeks, respectively). Thus, the performance status was not of prognostic value in the histologic subgroups experiencing the best response rate. There were two treatment-related deaths, but otherwise the toxicity of BEP was acceptable. Only four of the 119 treatment cycles were followed by fever even though there was significant neutropenia (0.5 X 10(9)/L) after 20 of 97 treatment cycles. The majority of patients receiving BEP experienced relief of cough, hemoptysis, pain, and fatigue associated with their disease. There was a good correlation between objective responses and palliation of symptoms. Thus, BEP offers good palliation, particularly for patients with squamous-cell and large-cell lung cancer.


Sign in / Sign up

Export Citation Format

Share Document